Orphan Drug Incentives Would Go Further Than Regulatory Reform - Reardan
Eleos VP-Regulatory Affairs Dayton Reardan suggested that instead of focusing on problems with FDA's review process for rare disease drugs, government should create more development incentives in order to bring more drugs for rare diseases to market
You may also be interested in...
FDA may have to exit its drug review comfort zone and accept more trials outside the classic double-blind, placebo-controlled realm to promote more orphan drug development, industry and advocacy organizations told the agency
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials